

- 16) Ikeda H, Tateishi R, Enooku K, Yoshida H, Nakagawa H, Masuzaki R, Kondo Y, Goto T, Shiina S, Kume Y, Tomiya T, Inoue Y, Nishikawa T, Ohtomo N, Tanoue Y, Ono T, Koike K, Yatomi Y. Prediction of hepatocellular carcinoma development by plasma ADAMTS13 in chronic hepatitis B and C. *Cancer Epidemiol Biomarkers Prev* 2011; 20(10):2204-2211. (2010IF 4.1)
- 17) Watanabe S, Enomoto N, Koike K, Izumi N, Takikawa H, Hashimoto E, Moriyasu F, Kumada H, Imawari M; PERFECT Study Group. Cancer preventive effect of pegylated interferon α -2b plus ribavirin in a real-life clinical setting in Japan: PERFECT interim analysis. *Hepatol Res* 2011;41(10):955-964.
- 18) Otsuka M, Takata A, Yoshikawa T, Kojima K, Kishikawa T, Shibata C, Takekawa M, Yoshida H, Omata M, Koike K. Receptor for Activated Protein Kinase C: Requirement for Efficient MicroRNA Function and Reduced Expression in Hepatocellular Carcinoma. *PLoS One*. 2011;6(9):e24359. Epub 2011 Sep 15. PubMed PMID: 21935400.
- 19) Uchino K, Tateishi R, Shiina S, Kanda M, Masuzaki R, Kondo Y, Goto T, Omata M, Yoshida H, Koike K. Hepatocellular carcinoma with extrahepatic metastasis: Clinical features and prognostic factors. *Cancer* 2011;117(19):4475-4483.
- 20) Takata A, Otsuka M, Kojima K, Yoshikawa T, Kishikawa T, Yoshida H, Koike K. MicroRNA-22 and microRNA-140 suppress NF- κ B activity by regulating the expression of NF- κ B coactivators. *Biochem Biophys Res Commun* 2011;411(4):826-831.
- 21) Wakita T, Suzuki T, Evans MJ, Shimotohno K, Chayama K, Matsuura Y, Hijikata M, Moriishi K, Seya T, Enomoto N, Koike K, Kato N, Kanto T, Hotta H. Will There Be an HCV Meeting in 2020? Summary of the 17th International Meeting on Hepatitis C Virus and Related Viruses. *Gastroenterology* 2011 Jul;141(1):e1-5.
- 22) Nakagawa H, Hirata Y, Takeda K, Hayakawa Y, Sato T, Kinoshita H, Sakamoto K, Nakata W, Hikiba Y, Omata M, Yoshida H, Koike K, Ichijo H, Maeda S. Apoptosis signal-regulating kinase 1 inhibits hepatocarcinogenesis by controlling the tumor-suppressing function of stress-activated MAPK. *Hepatology* 2011;54(1):185-195.
- 23) Kojima K, Takata A, Vadnais C, Otsuka M, Yoshikawa T, Akanuma M, Kondo Y, Kang YJ, Kishikawa T, Kato N, Xie Z, Zhang WJ, Yoshida H, Omata M, Nepveu A, Koike K. MicroRNA122 is a key regulator of α -fetoprotein expression and biologically aggressive behavior of hepatocellular carcinoma. *Nat Commun* 2011 Jun 7;2:338. doi: 10.1038/ncomms1345. PubMed PMID: 21654638. (on-line journal)
- 24) Tsukada K, Sugawara Y, Kaneko J, Tamura S, Tachikawa N, Morisawa Y, Okugawa S, Kikuchi Y, Oka S, Kimura S, Yatomi Y, Makuuchi M, Kokudo N, Koike K. Living donor liver transplantations in HIV- and hepatitis C virus-coinfected hemophiliacs: Experience in a Single Center. *Transplantation* 2011;91(11):1261-1264.
- 25) Koshiyama A, Ichibangase T, Moriya K, Koike K, Yazawa I, Imai K. Liquid chromatographic separation of proteins derivatized with a fluorogenic reagent at cysteinyl residues on a non-porous column for differential proteomics analysis. *J Chromatogr A* 2011;1218(22):3447-3452.

- 26) Kumar V, Kato N, Urabe Y, Takahashi A, Muroyama R, Hosono N, Otuska M, Tateishi R, Omata M, Nakagawa H, Koike K, Kamatani N, Kubo M, Nakamura Y, Matsuda K. Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma. *Nat Genet* 2011;43(5):455-458.
- 27) Nakagawa H, Ikeda H, Nakamura K, Ohkawa R, Masuzaki R, Tateishi R, Yoshida H, Watanabe N, Tejima K, Kume Y, Iwai T, Suzuki A, Tomiya T, Inoue Y, Nishikawa T, Ohtomo N, Tanoue Y, Omata M, Igarashi K, Aoki J, Koike K, Yatomi Y. Autotaxin as a novel serum marker of liver fibrosis. *Clin Chim Acta* 2011;412(13-14):1201-1206.
- 28) Kershenobich K, Razavi HA, Cooper CL, Alberti A, Dusheiko GM, Pol S, Zuckerman E, Koike K, Han K-H, Wallace CM, Zeuzem S, Negro F. The global health burden of hepatitis C virus infection. *Liver Int* 31(S2):4-17, 2011.
- 29) Sievert W, Altraif I, Razavi HA, Abdo A, Ahmed EA, AlOmair A, Amarapurkar D, Chen C-H, Dou X, El Khayat H, elShazly M, Esmat G, Guan R, Han K-H, Koike K, Largen A, McCaughan G, Mogawer S, Monis A, Nawaz A, Piratvisuth T, Sanai FM, Sharara AI, Sibbel S, Sood A, Suh DJ, Wallace C, Young K, Negro F. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. *Liver Int* 31(S2):61-80, 2011.
- 30) Yasui K, Hashimoto E, Komorizono Y, Koike K, Arai S, Imai Y, Shima T, Kanbara Y, Saibara T, Mori T, Kawata S, Uto H, Takami S, Sumida Y, Takamura T, Kawanaka M, Okanoue T; The Japan NASH Study Group, The Ministry of Health, Labour and Welfare of Japan. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. *Clin Gastroenterol Hepatol* 2011;9(5):428-433. (2009; 5.642)
- 31) Koike K, Miyoshi H, Yotsuyanagi H, Moriya K. Effect of treatment with polyunsaturated fatty acids on HCV-or diet-induced fatty liver. *J Hepatol* 2011;54:1326.
- 32) Masuzaki R, Shiina S, Tateishi R, Yoshida H, Goto E, Sugioka Y, Kondo Y, Goto T, Ikeda H, Omata M, Koike K. Utility of contrast enhanced ultrasonography with sonazoid in radiofrequency ablation for hepatocellular carcinoma. *J Gastroenterol Hepatol* 2011;26(4):759-764.
- 33) Miyoshi H, Moriya K, Tsutsumi T, Shinzawa S, Fujie H, Shintani Y, Fujinaga H, Goto K, Todoroki T, Suzuki T, Miyamura T, Matsuura Y, Yotsuyanagi H, Koike K. Pathogenesis of lipid metabolism disorder in hepatitis C: polyunsaturated fatty acids counteract lipid alterations induced by the core protein. *J Hepatol* 2011;54:432-438.
- 34) Kondo Y, Shiina S, Tateishi R, Arano T, Uchino K, Enooku K, Goto E, Nakagawa H, Masuzaki R, Asaoka Y, Fujie H, Goto T, Omata M, Yoshida H, Koike K. Intrahepatic bile duct dilatation after percutaneous radiofrequency ablation for hepatocellular carcinoma: impact on patient's prognosis. *Liver Int* 2011;31:197-205.
- 35) Koike K, Tsutsumi T, Yotsuyanagi H, Moriya K. Lipid metabolism and pathogenesis of liver disease in hepatitis C viral infection. *Oncology* 2010;78 Suppl 1:24-30.
- 36) Tejima K, Masuzaki R, Ikeda H,

- Yoshida H, Tateishi R, Sugioka Y, Kume Y, Okano T, Iwai T, Gotoh H, Katoh S, Suzuki S, Yatomi Y, Omata M, Koike K. Thrombocytopenia is more severe in advanced chronic hepatitis C than B with the same grade of splenomegaly. *J Gastroenterol* 2010;45:876-884.
- 37) Ishizaka N, Ishizaka Y, Toda E, Yamakado M, Koike K, Nagai R. Association between gamma-glutamyl transferase levels and insulin resistance according to alcohol consumption and number of cigarettes smoked. *J Atheroscler Thromb* 2010;17:476-485.
- 38) Ohtomo N, Tomiya T, Tanoue Y, Inoue Y, Nishikawa T, Ikeda H, Seyama Y, Kokudo N, Shibahara J, Fukayama M, Koike K, Shirataki H, Fujiwara K. Expression of alpha-taxilin in hepatocellular carcinoma correlates with growth activity and malignant potential of the tumor. *Int J Oncol* 2010;37:1417-1423.
- 39) Ikeda H, Ohkawa R, Watanabe N, Nakamura K, Kume Y, Okubo S, Yokota H, Tomiya T, Inoue Y, Nishikawa T, Ohtomo N, Tanoue Y, Koike K, Yatomi Y. Plasma sphingosine 1-phosphate level is reduced in patients with chronic liver disease caused by hepatitis C. *Clin Chim Acta* 2010;411:765-770.
- 40) Okuse C, Yotsuyanagi H, Yamada N, Okamoto M, Ikeda H, Kobayashi M, Fukuda Y, Takahashi H, Nagase Y, Suzuki Y, Matsunaga K, Ishii T, Matsumoto N, Koike K, Suzuki M, Itoh F. Effect of nucleoside analogue-interferon sequential therapy on patients with acute exacerbation of chronic hepatitis B. *Hepatology* 2010; 40: 461-469.
- 41) Kanamori H, Yuhashi K, Ohnishi S, Koike K, Kodama T. RNA dependent RNA polymerase of hepatitis C virus binds to its coding region RNA stem-loop structure, 5BSL3.2, and its negative strand. *J Gen Virol* 2010;91:1207-1212.
- 42) Moriya K, Miyoshi H, Shinzawa S, Tsutsumi T, Fujie H, Goto K, Shintani Y, Yotsuyanagi H, Koike K. Hepatitis C virus core protein compromises iron-induced activation of antioxidants in mice and HepG2 cells. *J Med Virol* 2010;82:776-792.
- 43) Molina-Jiménez F, Benedicto I, Murata M, Martín-Vílchez S, Seki T, Pintor-Toro JA, Tortolero M, Moreno-Otero R, Okazaki K, Koike K, Barbero JL, Matsuzaki K, Majano PL, López-Cabrera M. Expression of pituitary tumor transforming gene 1 (PTTG1)/securin in hepatitis B virus-associated liver diseases: Evidence for a hepatitis B virus X protein-mediated inhibition of PTTG1 ubiquitination and degradation. *Hepatology* 2010;51:777-787.
- 44) Hmwe SS, Aizakia H, Date T, Murakami K, Ishii K, Miyamura T, Koike K, Wakita T, Suzuki T. Identification of hepatitis C virus genotype 2a replicon variants with reduced susceptibility to ribavirin. *Antiviral Res* 2010;85:520-524.
- 45) Watanabe S, Enomoto N, Koike K, Izumi N, Takikawa H, Hashimoto E, Moriyasu F, Kumada H, Imawari M, PERFECT STUDY GROUP. Prolonged treatment with PEG-IFN a-2b and ribavirin can improve SVR in chronic hepatitis C genotype 1 patients with late response in a clinical real-life setting in Japan. *Hepatology* 2010;40:135-144.
- 46) Koike K, Moriya K, Matsuura Y. Animal models for hepatitis C and related liver disease. *Hepatology* 2010;40:69-82.

- 47) Moriya K, Miyoshi H, Tsutsumi T, Shinzawa S, Fujie H, Shintani Y, Yotsuyanagi H, Moriishi K, Matsuura Y, Suzuki T, Miyamura T, Koike K. Tacrolimus ameliorates metabolic disturbance and oxidative stress caused by hepatitis C virus core protein: Analysis using mouse model and cultured cells. *Am J Pathol* 2009;175:1515-1524.
- 48) Tsutsumi T, Matsuda M, Aizaki H, Moriya K, Miyoshi H, Fujie H, Shintani Y, Yotsuyanagi H, Miyamura T, Suzuki T, Koike K. Proteomics analysis of mitochondrial proteins reveals overexpression of a mitochondrial protein chaperone, prohibitin, in cells expressing hepatitis C virus core protein. *Hepatology* 2009;50:378-386.
- 49) Yotsuyanagi H, Kikuchi Y, Tsukada K, Nishida K, Kato M, Sakai H, Takamatsu J, Hige S, Chayama K, Moriya K, Koike K. Chronic hepatitis C in patients coinfecting with human immunodeficiency virus in Japan: a retrospective multicenter analysis. *Hepatol Res* 2009;39:657-663.
- 50) Ishizaka Y, Ishizaka N, Tani M, Toda A, Toda EI, Koike K, Nagai R, Yamakado M. Association between changes in obesity parameters and incidence of chronic kidney disease in Japanese individuals. *Kidney Blood Press Res* 2009;32:141-149.
- 51) Murata M, Matsuzaki K, Yoshida K, Sekimoto G, Uemura Y, Sakaida N, Fujisawa J, Seki T, Koike K, Okazaki K. Hepatitis B virus X protein shifts hepatic Smad3-mediated signaling from tumor-suppression to oncogenesis in chronic hepatitis B. *Hepatology* 2009;49:1203-1217.
- 52) Yanagimoto S, Tatsuno K, Okugawa S, Kitazawa T, Tsukada K, Koike K, Kodama T, Kimura S, Shibasaki Y, Ota Y. A single amino acid of toll-like receptor 4 that is pivotal for its signaltransduction and subcellular localization. *J Biol Chem* 2009;284:3513-3520.
- 53) Ishizaka N, Ishizaka Y, Yamakado M, Toda E, Koike K, Nagai R. Association between metabolic syndrome and carotid atherosclerosis in individuals without diabetes based on the oral glucose tolerance test. *Atherosclerosis* 2009;204:619-623.
- 54) Koike K. Steatosis, Liver injury and hepatocarcinogenesis in hepatitis C viral infection. *J Gastroenterol* 2009;44supl:82-88.
- 55) Ichibangase T, Moriya K, Koike K, Imai K. Limitation of immunoaffinity column for the removal of abundant proteins from plasma in quantitative plasma proteomics. *Biomed Chromatogr* 2009;23:480-487.

H. 知的財産権の出願・登録状況

1. 特許取得

「肝細胞癌発生予測因子としての血中 ADAMTS13」 知的財産管理番号 12B10Y001-1 出願日 平成 22 年 11 月 5 日 発明者 池田均、矢富裕、建石良介、小池和彦、小野智子

III. 研究成果の刊行に関する一覧表

研究成果の刊行に関する一覧表
(2009年4月1日～2012年3月31日迄)

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
紙屋康之、 田中基彦、 佐々木裕	アルコールと肝臓	高後裕	最新医学別冊 新しい診断の ABC 62 「アルコール 性肝障害」	最新医学社	東京	2009	141-149

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Mohd-Ismail NK, Deng L, Sukumaran SK, Yu VC, <u>Hotta H</u> , Tan YJ.	The hepatitis C virus core protein contains a BH3 domain that regulates apoptosis through specific interaction with human MCL-1.	J Virol	83 (19)	9993-10006,	2009
Bungyoku Y, Shoji I, Makine T, Adachi T, Hayashida K, Nagano-Fujii M, Ide Y, Deng L, <u>Hotta H</u> .	Efficient production of infectious hepatitis C virus with adaptive mutations in cultured hepatoma cells.	J Gen Virol	90(7)	1681-1691,	2009
Kasai D, Adachi T, Deng L, Nagano-Fujii M, Sada K, Ikeda M, <u>Kato N</u> , Ide Y, Shoji I, <u>Hotta H</u> .	HCV replication suppresses cellular glucose uptake through down-regulation of cell surface expression of glucose transporters.	J Hepatol	50	883-894,	2009
Amako Y, Sarkeshik A, <u>Hotta H</u> , Yates J 3rd, Siddiqui A.	Role of oxysterol binding protein in hepatitis C virus infection.	J Virol	83 (18)	9237-9246,	2009

Shimoji T, Murakami K, Sugiyama Y, Matsuda M, Inubushi S, Nasu J, Shirakura M, Suzuki T, Wakita T, Kishino T, <u>Hotta H</u> , Miyamura T, Shoji I.	Identification of annexin A1 as a novel substrate for E6AP-mediated ubiquitylation.	J Cell Biochem.	106 (6)	1123-1135,	2009
Kim S R, Imoto S, Mita K, Taniguchi M, Sasase N, Muramatsu A, Kudo M, Kitai S, El-Shamy A, <u>Hotta H</u> , Hayashi Y.	Pegylated interferon plus ribavirin combination therapy for chronic hepatitis C with high viral load of serum HCV RNA, genotype 1b, discontinued on attaining sustained virological response in week 16 after onset of acute pancreatitis.	Digestion	79(1)	36-39	2009
Sanjo M, Saito T, Ishii R, Nishise Y, Haga H, Okumoto K, Ito J, Watanabe H, Saito K, Togashi H, Fukuda K, Imai Y, El-Shamy A, Deng L, Shoji I, <u>Hotta H</u> , Kawata S.	Secondary structure of the amino-terminal region of HCV NS3 and virological response to pegylated interferon plus ribavirin therapy for chronic hepatitis C.	J Med Virol	82(8)	1364-1370	2010
Hayashida K, Shoji I, Deng L, Jiang D-P, Ide Y-H, <u>Hotta H</u> .	17 β -Estradiol inhibits the production of infectious particles of hepatitis C virus.	Microbiol Immunol	54 (11)	684-690	2010
Nasu J, Murakami K, Miyagawa S, Yamashita R, Ichimura T, Wakita T, <u>Hotta H</u> , Miyamura T, Suzuki T, Satoh T, Shoji I.	E6AP ubiquitin ligase mediates ubiquitin-dependent degradation of peroxiredoxin 1.	J Cell Biochem	111 (3)	676-685	2010
Sasase N, Kim SR, Kudo M, Kim KI, Taniguchi M, Imoto S, Mita K, Hayashi Y, Shoji I, El-Shamy A, <u>Hotta H</u> .	Outcome and early viral dynamics with viral mutation in PEG-IFN/RBV therapy for chronic hepatitis in patients with high viral loads	Intervirolgy	53(1)	49-54	2010

	of serum HCV RNA genotype 1b.				
Kim SR, Imoto S, Kudo M, Nakajima T, Ando K, Mita K, Fukuda K, Hong HS, Lee YH, Nakashima K, Shoji I, Nagano-Fujii M, <u>Hotta H</u> , Hayashi Y.	Autoimmune thrombocytopenic purpura during pegylated interferon alpha treatment for chronic hepatitis C	Intern Med	49 (12)	1119-1122	2010
Kim SR, Imoto S, Kudo M, Mita K, Taniguchi M, Kim KI, Sasase N, Shoji I, Nagano-Fujii M, El-Shamy A, <u>Hotta H</u> , Nagai T, Nagata Y, Hayashi Y.	Double-filtration plasmapheresis plus IFN for HCV-1b patients with non-sustained virological response to previous combination therapy: early viral dynamics	Intervirology	53(1)	44-48	2010
Deng L, Shoji I, Ogawa W, Kaneda S, Soga T, Jiang DP, Ide YH, <u>Hotta H</u> .	Hepatitis C virus infection promotes hepatic gluconeogenesis through an NS5A-mediated, FoxO1-dependent pathway.	J Virol	85 (17)	8556-8568	2011
Nakashima K, Takeuchi K, Chihara K, <u>Hotta H</u> , Sada K.	Inhibition of hepatitis C virus replication through AMP-activated protein kinase-dependent and -independent pathways.	Microbiol Immunol	55 (11)	774-782	2011
El-Shamy A, Shoji I, Saito T, Watanabe H, Ide YH, Deng L, Kawata S, <u>Hotta H</u> .	Sequence heterogeneity of NS5A and core proteins of hepatitis C virus and virological responses to pegylated -interferon/ribavirin combination therapy.	Microbiol Immunol	55(6)	418-426	2011
El-Shamy A, Kim SR, Ide YH, Sasase N, Imoto S, Deng L, Shoji I, <u>Hotta H</u> .	Polymorphisms of hepatitis C virus NS5A and core proteins and clinical outcome of pegylated	Intervirology	55(1)	1-11	2012

	Interferon/Ribavirin combination therapy.				
Kim SR, Saito J, Imoto S, Komaki T, Nagata Y, Nakajima T, Ando K, Fukuda K, Otono Y, Kim KI, Ohtani A, Sugimoto K, Hasegawa Y, Fujinami A, Ohta M, <u>Hotta H</u> , Maekawa Y, Hayashi Y, Kudo M.	Correlation between insulin resistance and outcome of pegylated interferon and ribavirin therapy, hepatic steatosis, hepatic fibrosis in chronic hepatitis C-1b and high viral load.	Digestion	84 Suppl 1	5-9	2011
Kim SR, Saito J, Imoto S, Komaki T, Nagata Y, Kim KI, Sasase N, Kimura N, Sasatani K, Konishi E, Hasegawa Y, Fujinami A, Ohta M, El-Shamy A, Tanaka Y, Sugano M, Sakashita M, Nakamura A, Tsuchida S, Makino T, Kawada T, Nakajima T, Morikawa T, Muramatsu A, Kasugai H, <u>Hotta H</u> , Kudo M.	Double-filtration plasmapheresis plus interferon- β for HCV-1b patients with non-sustained virological response to previous combination therapy.	Digestion	84 Suppl 1	10-16	2011
Sasayama M, Shoji I, Adianti M, Jiang D-P, Deng L, Saito T, Watanabe H, Kawata S, Aoki C, <u>Hotta H</u> .	A point mutation at ASN-534 that disrupts a conserved <i>N</i> -glycosylation motif of the E2 glycoprotein of hepatitis C virus markedly enhances the sensitivity to antibody neutralization.	J Med Virol	84(2)	229-234	2012
Shoji I, Deng L, <u>Hotta H</u> .	Molecular mechanism of hepatitis C virus-induced glucose metabolic disorders.	Front Microbiol	2:A27 8	1-5	2012
Kamada K, Shoji I, Deng L, Aoki C, Ratnoglik SL,	Generation of a recombinant reporter hepatitis C virus	Microbes Infect	14(1)	69-78	2012

Wakita T, <u>Hotta H.</u>	useful for the analyses of virus entry, intra-cellular replication and virion production.				
El-Shamy A, Shoji I, Kim SR, Ide Y, Imoto S, Deng L, Yoon S, Fujisawa T, Tani S, Yano Y, Seo Y, Azuma T, <u>Hotta H.</u>	Sequence heterogeneity in NS5A of hepatitis C virus genotypes 2a and 2b and clinical outcome of pegylated-interferon/ribavirin therapy.	PLoS ONE	7(2)	e30513	2012
Wakita T, Suzuki T, Evans MJ, Shimotohno K, Chayama K, Matsuura Y, Hijikata M, <u>Moriishi K.</u> , Seya T, Enomoto N, <u>Koike K.</u> , Kato N, Kanto T, <u>Hotta H.</u>	Will there be an HCV Meeting in 2020? Summary of the 17th International Meeting on Hepatitis C Virus and Related Viruses.	Gastroenterology	141(1)	e1-5	2011
Kim SR, El-Shamy A, Imoto S, Kim KI, Ide YH, Deng L, Shoji I, Tanaka Y, Hasegawa Y, Ota M, <u>Hotta H.</u>	Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotype 1b and high viral load.	J Gastroenterol		In press	2012
勝二郁夫, El-ShamyAhmed, <u>堀田博</u>	NS5A-IRRDR 変異数.	医学のあゆみ	239(12-13)	1208-1211	2011
勝二郁夫, El-ShamyAhmed, <u>堀田博</u>	C型肝炎ウイルス NS5A 領域の ISDR・IRRDR とインターフェロン治療効果予測.	肝胆膵	63(6)	1063-1069	2011
Yokozawa J, Sasaki T, Ohwada K, Sasaki Y, Ito JI, Saito T, <u>Kawata S.</u>	Down-regulation of hepatic stearyl-CoA desaturase 1 expression by angiotensin II receptor blocker in the obese <i>fa/fa</i> Zucker rat: possible role in amelioration of insulin resistance and hepatic steatosis.	J Gastroenterol	44(6)	583-591	2009

Saito T, Nishise Y, Makino N, Haga H, Ishii R, Okumoto K, Ito JI, Watanabe H, Saito K, Takeda H, Togashi H, Kubota I, Daimon M, Kato T, <u>Kawata S.</u>	Impact of metabolic syndrome on elevated serum alanine aminotransferase levels in the Japanese population.	Metabolism	58(8)	1067-1075	2009
Takeda H, Nishise S, Fukui T, Fujishima S, Orii T, Otake S, Sato T, Sasaki Y, <u>Kawata S.</u>	Plasma level of granulocyte-colony stimulating factor during granulocyte and monocyte adsorptive apheresis in patients with ulcerative colitis.	Hepato-gastroenterol	56 (90)	348-351	2009
Nishise S, Takeda Y, Nishise Y, Fujishima S, Orii T, Otake S, Sato T, Sasaki Y, Takeda H, <u>Kawata S.</u>	Biological effect of anaphylatoxin C5a on the generation of anti-inflammatory substances in leukocyte adsorption.	Ther Apher Dial	13(6)	509-514	2009
Fujishima S, Takeda H, <u>Kawata S,</u> Yamakawa M	The relationship between the expression of the glucocorticoid receptor in biopsied colonic mucosa and the glucocorticoid responsiveness of ulcerative colitis patients.	Clin Immunol	133 (2)	208-217	2009
柄沢 哲、富樫 整、齋藤貴史、 <u>河田純男</u> 、他	インターフェロン療法が著効した特発性血小板減少性紫斑病を合併した C 型肝炎の 1 例.	日本消化器病学会雑誌	106 (3)	405-410	2009
齋藤貴史、西瀬雄子、石井里佳、渡辺久剛、鈴木克典、 <u>河田純男</u>	HCV NS3 蛋白質多型性と C 型慢性肝炎の予後・治療効果予測.	日本消化器病学会雑誌	106 (4)	502-507	2009
Nishise Y, Saito T, Makino N, Okumoto K, Ito J, Watanabe H, Saito K, Togashi H, Ikeda C, Kubota I, Daimon M, Kato T,	Relationship between alcohol consumption and serum adiponectin levels: The Takahata Study - A cross-sectional	J Clin Endocrinol Metab	95(8)	3828-3835	2010

Fukao A, <u>Kawata S.</u>	study of a healthy Japanese population.				
Hattori E, Shu HJ, Saito T, Okumoto K, Haga H, Yokozawa J, Ito J, Watanabe H, Saito K, Togashi H, <u>Kawata S.</u>	Expression of the RNA-binding protein Musashi1 in adult liver stem-like cells.	Hepatol Res	40(4)	432-437	2010
Nishise S, Takeda Y, Fujishima S, Orii T, Sato T, Sasaki Y, Nishise Y, Takeda H, <u>Kawata S.</u>	Release of interleukin 1 receptor antagonist by combining a leukocyte adsorption carrier with ulinastatin.	Ther Apher Dial	14(4)	386-391	2010
伊藤純一、鈴木明彦、宇賀神智、佐藤智佳子、芳賀弘明、石井里佳、三條麻衣、奥本和夫、西瀬雄子、渡辺久剛、齋藤孝治、齋藤貴史、河田純男	高齢者に発症した肝動脈化学塞栓療法(TACE)後のガス産生肝膿瘍の1例	日本高齢消化器病学会誌	12	83-87	2010
Soga T, Sugimoto M, Honma M, Mori M, Igarashi K, Kashikura K, Ikeda S, Hirayama A, Yamamoto T, Yoshida H, Otsuka M, Tsuji S, Yatomi Y, Sakuragawa T, Watanabe H, Nihei K, <u>Saito T</u> , Kawata S, Suzuki H, Tomita M, Suematsu M.	Serum metabolomics reveals γ -glutamyl dipeptides as biomarkers for discrimination among different forms of liver disease.	J Hepatol	55(4)	896-905	2011
<u>Saito T</u> , Okumoto K, Haga H, Nishise Y, Ishii R, Sato C, Watanabe H, Okada A, Ikeda M, Togashi H, Ishikawa T, Terai S, Sakaida I, Kawata S.	Potential therapeutic application of intravenous bone marrow infusion in patients with alcoholic liver cirrhosis.	Stem Cells Dev	20(9)	1503-1510	2011
Ishii R, Togashi H, Iwaba A, Sato C, Haga H, Sanjo M, Okumoto K, Nishise	(99m)Tc-GSA SPECT analysis was clinically useful to evaluate the effect of interferon in a	Ann Nucl Med	25(7)	520-523	2011

Y, Ito JI, Watanabe H, Saito K, Okada A, Takahashi K, <u>Saito T</u> , Kawata S.	patient with interferon non-responsive chronic hepatitis C.				
Ito J, <u>Saito T</u> , Iwaba A, Suzuki Y, Sanjo M, Ishii R, Sato C, Haga H, Okumoto K, Nishise Y, Watanabe H, Saito K, Togashi H, Kawata S.	A case of monocular blindness as the initial presentation of hepatocellular carcinoma with skull metastasis.	Clin J Gastroenterol	4	273-277	2011
渡辺久剛, 斎藤貴史, 富田恭子, 佐藤智佳子, 石井里佳, 芳賀弘明, 奥本和夫, 西瀬雄子, 河田純男	B型肝炎ウイルスジェノタイプ B 型感染高浸淫地区における感染実態の変遷	肝臓	52 (11)	753-755	2011
Takai A, Toyoshima T, Uemura M, Kitawaki Y, <u>Marusawa H</u> , Hiai H, Yamada S, Okazaki IM, Honjo T, Chiba T, Kinoshita K.	A novel mouse model of hepatocarcinogenesis triggered by AID causing deleterious p53 mutations.	Oncogene	28 (4)	469-478	2009
Wada M, <u>Marusawa H</u> , Yamada R, Nasu A, Osaki Y, Kudo M, Nabeshima M, Fukuda Y, Chiba T, Matsuda F.	Association of genetic polymorphisms with interferon-induced haematologic adverse effects in chronic hepatitis C patients.	J Viral Hepat	16	388-396	2009
Ikeuchi K, <u>Marusawa H</u> , Fujiwara M, Matsumoto Y, Endo Y, Watanabe T, Iwai A, Sakai Y, Takahashi R, Chiba T.	Attenuation of proteolysis-mediated cyclin E regulation by alternatively spliced Parkin in human colorectal cancers.	Int J Cancer	125	2029-2035	2009
Matsumoto Y, <u>Marusawa H</u> , Kinoshita K, Niwa Y, Sakai Y, Chiba T.	Upregulation of activation-induced cytidine deaminase causes genetic aberrations at the CDKN2b-CDKN2a in gastric cancer.	Gastroenterology	139	1984-1994	2010
<u>Marusawa H</u> , Chiba T.	Helicobacter pylori-induced activation-induced	Curr Opin Immunol	22	442-447	2010

	cytidine deaminase expression and carcinogenesis.				
Endo Y, <u>Marusawa H</u> , Chiba T.	Involvement of activation-induced cytidine deaminase in the development of colitis-associated colorectal cancers.	J Gastroenterol	46	6-1	2011
Nasu A, <u>Marusawa H</u> , Ueda Y, Nishijima N, Takahashi K, Osaki Y, Yamashita Y, Inokuma T, Tamada T, Fujiwara T, Sato F, Shimizu K, Chiba T.	Genetic heterogeneity of hepatitis C virus in association with antiviral therapy determined by ultra-deep sequencing.	PLoS ONE	6	e24907	2011
Morita S, Matsumoto Y, Okuyama S, Ono K, Kitamura Y, Tomori A, Oyama T, Amano Y, Kinoshita Y, Chiba T, <u>Marusawa H</u> .	Bile acid-induced expression of activation-induced cytidine deaminase during the development of Barrett's oesophageal adenocarcinoma.	Carcinogenesis	32	1706-1712	2011
Okuyama S, <u>Marusawa H</u> , Matsumoto T, Ueda Y, Matsumoto Y, Endo Y, Takai A, Chiba T.	Excessive activity of APOBEC2 contributes to liver and lung tumorigenesis.	Int J Cancer	130 (6)	1294-1301	2012
Takai A, <u>Marusawa H</u> , Minaki Y, Watanabe T, Nakase H, Tsujimoto G, Chiba T.	Targeting activation-induced cytidine deaminase prevents colon cancer.	Oncogene		In press	2012
Ikuta Y, Hayashida Y, Hirata K, Irie A, Senju S, Nakatsura T, Monji M, <u>Sasaki Y</u> , Baba H, Nishimura Y.	Identification of the H2-Kd-restricted CTL epitopes of a tumor-associated antigen, SPARC, which can stimulate antitumor immunity without causing autoimmune disease in mice.	Cancer Sci	100	132-137	2009
Yokoo K, Hamada A,	Effects of oral	Ther Drug Monit	31	400-403	2009

Tazoe K, <u>Sasaki Y</u> , Saito H.	administered S-1 on the pharmacokinetics of SN-38, irinotecan active metabolite, in patients with advanced colorectal cancer.				
佐々木裕	特集：細胞死をめぐる最近のトピックス 細胞死と免疫監視機構からの回避	Surgery Frontier	16 卷	60-65	2009
佐々木裕	特集：肝細胞癌の治療2009～2011 知っておきたい肝炎ウイルスと肝発癌	コンセンサス 癌治療	8 卷	121-125	2009
Yokomine K, Senju S, Nakatsura T, Irie A, Hayashida Y, Ikuta Y, Harao M, Imai K, Baba H, Iwase H, Nomori H, Takahashi K, Daigo Y, Tsunoda T, Nakamura Y, <u>Sasaki Y</u> , Nishimura Y.	The forkhead box M1 transcription factor as a candidate of target for anti-cancer immunotherapy.	Int J Cancer	126	2153-2163	2010
Ikeda M, Maeda S, Ashihara H, Nagahama H, Tanaka M, <u>Sasaki Y</u> .	Transcatheter arterial infusion chemotherapy with cisplatin-lipiodol suspension in patients with hepatocellular carcinoma.	J Gastroenterol	45(1)	60-67	2010
Dessouki O, Kamiya Y, Nagahama H, Tanaka M, Suzu S, <u>Sasaki Y</u> , Okada S.	Chronic hepatitis C viral infection reduced NK cell frequency and suppresses cytokine secretion: Reversion by anti-viral treatment.	Biochem Biophys Res Commun	393	331-337	2010
Naoe H, Araki K, Nagano O, Kobayashi Y, Ishizawa J, Chiyoda T, Shimizu T, Yamamura K, <u>Sasaki Y</u> , Saya H,	The anaphase-promoting complex/cyclosome activator cdh1 modulates Rho GTPase by targeting p190 RhoGAP for	Mol Cell Biol	30 (16)	3994-4005	2010

Kuninaka S.	degradation.				
Sasaki Y.	Insulin resistance and hepatocarcinogenesis.	Clin J Gastroenterol	3	271-278	2010
福林光太郎, 田中基彦 佐々木裕.	特集 肝胆膵 薬物治療学の進歩 - この30年 低用量 CDDP/5-FU 肝動注化学療法	肝胆膵	61	1125-1130	2010
Taura N, Fukushima N, Yatsuhashi H, Takami Y, Seike M, Watanabe H, Mizuta T, Sasaki Y, Nagata K, Tabara A, Komorizono Y, Taketomi A, Matsumoto S, Tamai T, Muro T, Nakao K, Fukuizumi K, Maeshiro T, Inoue O, Sata M.	The incidence of hepatocellular carcinoma associated with hepatitis C infection decreased in Kyushu area.	Med Sci Monit	17	7-11	2011
Tateyama M, Yatsuhashi H, Taura N, Motoyoshi Y, Nagaoka S, Yanagi K, Abiru S, Komori A, Migita K, Nakamura M, Nagahama H, Sasaki Y, Miyakawa Y, Ishibashi H.	Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus.	J Gastroenterol	46	92-100	2011
Watanabe T, Ishihara Ko, Hirose A, Watanabe S, Hino S, Ojima H, Kanai Y, Sasaki Y, Nakao M.	Higher-order chromatin regulation and differential gene expression in the human tumor necrosis factor/lymphotoxin locus in hepatocellular carcinoma cells.	Mol Cell Biol		In press	2012
Taguwa S, Kambara H, Omori H, Tani H, Abe T, Mori Y, Suzuki T, Yoshimori T, Moriishi K, Matsuura Y.	Cochaperone activity of human butyrate-induced transcript 1 facilitates hepatitis C virus replication through an Hsp90-dependent pathway.	J Virol	83	10427-10436	2009

Suzuki R, <u>Moriishi K</u> , Fukuda K, Shirakura M, Ishii K, Shoji I, Wakita T, Miyamura T, Matsuura Y, Suzuki T.	Proteasomal turnover of hepatitis C virus core protein is regulated by two distinct mechanisms: a ubiquitin-dependent mechanism and a ubiquitin-independent but PA28gamma-dependent mechanism.	J Virol	83	2389-2392	2009
Kukihara H, <u>Moriishi K</u> , Taguwa S, Tani H, Abe T, Mori Y, Suzuki T, Fukuhara T, Taketomi A, Maehara Y, Matsuura Y.	Human VAP-C negatively regulates hepatitis C virus propagation.	J Virol	83	7959-7969	2009
Tripathi L P, Kataoka C, Taguwa S, <u>Moriishi K</u> , Mori Y, Matsuura Y, Mizuguchi K.	Network based analysis of hepatitis C virus Core and NS4B protein interactions.	Mol Biosyst	6	2539-2553	2010
Tanaka Y, Mori Y, Tani H, Abe T, <u>Moriishi K</u> , Kojima H, Nagano T, Okabe T, Suzuki T, Tatsumi M, Matsuura Y.	Establishment of an indicator cell system for hepatitis C virus.	Microbiol Immunol	54	206-220	2010
<u>Moriishi K</u> , Shoji I, Mori Y, Suzuki R, Suzuki T, Kataoka C, Matsuura Y.	Involvement of PA28gamma in the propagation of hepatitis C virus.	Hepatology	52	411-420	2010
Wen X, Abe T, Kukihara H, Taguwa S, Mori Y, Tani H, Kato N, Suzuki T, Tatsumi M, <u>Moriishi K</u> , Matsuura Y.	Elimination of hepatitis C virus from hepatocytes by a selective activation of therapeutic molecules.	PLoS One	6	e15967	2011
Taguwa S, Kambara H, Fujita N, Noda T, Yoshimori T, Koike K, <u>Moriishi K</u> , Matsuura Y.	Dysfunction of autophagy participates in vacuole formation and cell death in cells replicating hepatitis C virus.	J. Virol	85	13185-13194	2011

Kambara H, Tani H, Mori Y, Abe T, Katoh H, Fukuhara T, Taguwa S, <u>Moriishi K</u> , <u>Matsuura Y</u> .	Involvement of cyclophilin B in the replication of Japanese encephalitis virus.	Virology	412	211-219	2011
Kuroki M, Ariumi Y, Ikeda M, Dansako H, Wakita T, <u>Kato N</u> .	Arsenic trioxide inhibits hepatitis C virus RNA replication through modulation of the glutathione redox system and oxidative stress.	J Virol	83(5)	2338-2348	2009
<u>Kato N</u> , Mori K, Abe K, Dansako H, Kuroki M, Ariumi Y, Wakita T, Ikeda M.	Efficient replication systems for hepatitis C virus using a new hepatoma cell line.	Virus Res	146 (1-2)	41-50	2009
Abe K, Ikeda M, Ariumi Y, Dansako H, Wakita T, <u>Kato N</u> .	HCV genotype 1b chimeric replicon with NS5B of JFH1 exhibited resistance to cyclosporine A.	Arch Virol	154 (10)	1671-1677	2009
Yano M, Ikeda M, Abe K, Kawai Y, Kuroki M, Mori K, Dansako H, Ariumi Y, Ohkoshi S, Aoyagi Y, <u>Kato N</u> .	Oxidative stress induces anti-hepatitis C virus status via the activation of extracellular signal-regulated kinase.	Hepatology	50(3)	678-688	2009
Bender H, Wiesinger MY, Nordhoff C, Schoenherr C, Haan C, Ludwig S, Weiskirchen R, <u>Kato N</u> , Heinrich PC, Haan S.	Interleukin-27 displays interferon γ -like functions in human hepatoma cells and hepatocytes.	Hepatology	50	585-591	2009
Vollmer S, Kappl V, Kaczor J, Flgel D, Rolvering C, <u>Kato N</u> , Kietzman T, Behrmann I, Haan C.	Hypoxia-inducible factor 1 α is upregulated by Oncostatin M and participates in Oncostatin M signaling.	Hepatology	50	253-260	2009
Kawai Y, Ikeda M, Abe KI, Yano M, Ariumi Y, Dansako H, Yamamoto K, <u>Kato N</u> .	Development of an HCV relapse model using genome-length HCV RNA-harboring cells possessing the	Hepatology Res	39(9)	898-909	2009

	IFN-alpha-resistance phenotype.				
Nishimura G, Ikeda M, Mori K, Nakazawa T, Ariumi Y, Dansako H, <u>Kato N.</u>	Replicons from genotype 1b HCV-positive sera exhibit diverse sensitivities to anti-HCV reagents.	Antiviral Res	82(1)	42-50	2009
Dansako H, Ikeda M, Ariumi Y, Wakita T, <u>Kato N.</u>	Double-stranded RNA-induced interferon-beta and inflammatory cytokine production modulated by hepatitis C virus serine proteases derived from patients with hepatic diseases.	Arch Virol	154 (5)	801-810	2009
Ikeda M, Mori K, Ariumi Y, Dansako H, <u>Kato N.</u>	Oncostatin M synergistically inhibits HCV RNA replication in combination with interferon-alpha.	FEBS Lett	583 (9)	1434-1438	2009
Matsumoto A, Ichikawa T, Nakao K, Miyaaki H, Hirano K, Fujimoto M, Akiyama M, Miuma S, Ozawa E, Shibata H, Takeshita S, Yamasaki H, Ikeda M, <u>Kato N.</u> , Eguchi K.	Interferon-alpha-induced mTOR activation is an anti-hepatitis C virus signal via the phosphatidylinositol 3-kinase-Akt-independent pathway.	J Gastroenterol	44	856-863	2009
有海康雄、 <u>加藤宣之</u>	HCVによる発癌メカニズム 慢性肝炎から肝臓にいたるパスウェイ.	日本臨床	67 (増刊号3)	138-142	2009
Mori K, Ikeda M, <u>Ariumi Y.</u> , Kato N.	Gene expression profile of Li23, a new human hepatoma cell line that enables robust hepatitis C virus replication: Comparison with HuH-7 and other	Hepatol Res	40 (12)	1248-1253	2010

	hepatitic cell lines.				
Ikeda F, Dansako H, Nishimura G, Mori K, Kawai Y, Ariumi Y, Miyake Y, Takaki A, Nouse K, Iwasaki Y, Ikeda M, Kato N, Yamamoto K.	Amino acid substitutions of hepatitis C virus core protein are not associated with intracellular antiviral response to interferon- α in vitro.	Liver Int	30(9)	1324-1331	2010
有海康雄, 黒木美沙緒, 團迫浩方, 阿部健一, 池田正徳, 脇田隆字, 加藤宣之.	DNA 損傷センサー ATM キナーゼと Chk2 は C 型肝炎ウイルスの RNA 複製に必要である.	岡山医学会雑誌	122 (1)	9-16	2010
Ariumi Y, Kuroki M, Maki M, Ikeda M, Dansako H, Wakita T, Kato N.	The ESCRT system is required for hepatitis C virus production.	PLoS One	6(1)	e14517	2011
Ariumi Y, Kuroki M, Kushima Y, Osugi K, Hijikata M, Maki M, Ikeda M, Kato N.	Hepatitis C virus hijacks P-body and stress granule components around lipid droplets.	J Virol	85 (14)	6882-6892	2011
Mori K, Ikeda M, Ariumi Y, Dansako H, Wakita T, Kato N.	Mechanism of action of ribavirin in a novel hepatitis C virus replication cell system.	Virus Res	157 (1)	61-70	2011
Ueda Y, Mori K, Ariumi Y, Ikeda M, Kato N.	Plural assay systems derived from different cell lines and hepatitis C virus strains are required for the objective evaluation of anti-hepatitis C virus reagents.	Biochem Biophys Res Commun	409 (4)	663-668	2011
Ikeda M, Kawai Y, Mori K, Yano M, Abe K, Nishimura G, Dansako H, Ariumi Y, Wakita T, Yamamoto K, Kato N.	Anti-ulcer agent teprenone inhibits hepatitis C virus replication: potential treatment for hepatitis C.	Liver Int	31(6)	871-880	2011
有海康雄、加藤宣之	HCV による肝発癌機構	日本臨床	69 (増刊 4号)	64-68	2011